衞光生物(002880.SZ):上半年淨利升9.88%至7750.04萬元
格隆匯 8 月 20日丨衞光生物(002880.SZ)披露2020年半年度報告,實現營業收入4.08億元,同比增長13.04%;歸屬於上市公司股東的淨利潤7750.04萬元,同比增長9.88%;歸屬於上市公司股東的扣除非經常性損益的淨利潤7453.84萬元,同比增長13.08%;基本每股收益0.48元。
疫情期間,公司營銷中心積極應對市場變化,調整營銷策略,利用互聯網進行遠程辦公,營業收入同比增長達到13.04%。報告期內營銷中心一根據業務規模、內部流程,完善現有組織架構,明確部門分工,服務質量得到有效提升;二對按客户性質進行銷售定位,明確目標客户,優化資源配置,對於目標客户,靈活制定銷售策略;三注重與經銷商的戰略合作模式,通過業務優化整合、區域授權、產品價格體系管理建立長期合作關係;四利用互聯網辦公,保證與客户溝通順暢,及時滿足客户需求。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.